Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Armour

Showing results (281-290 of 292) with videos related to

Pageof 30
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 10, 2008
Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized, phase II studyLucio Crinò, Federico Cappuzzo, Petr Zatloukal, et al.
Journal of Medical Genetics|February 1, 1997
Pendred syndrome: evidence for genetic homogeneity and further refinement of linkageE Gausden, B Coyle, J A Armour, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 30, 2009
Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trialJean-Yves Douillard, Frances A Shepherd, Vera Hirsh, et al.
The Journal of Investigative Dermatology|December 18, 2009
Replication of LCE3C-LCE3B CNV as a risk factor for psoriasis and analysis of interaction with other genetic risk factorsUlrike Hüffmeier, Judith G M Bergboer, Tim Becker, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 10, 2019
Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trialW Shi, T Jiang, P Nuciforo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 9, 2017
Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trialW Shi, T Jiang, P Nuciforo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 28, 2018
Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trialW Shi, T Jiang, P Nuciforo, et al.
Teratogenesis, Carcinogenesis, and Mutagenesis|November 14, 2000
Molecular methods for the detection of mutationsC Monteiro, L A Marcelino, A R Conde, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 15, 2011
Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS)Masahiro Fukuoka, Yi-Long Wu, Sumitra Thongprasert, et al.
The New England Journal of Medicine|August 21, 2009
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinomaTony S Mok, Yi-Long Wu, Sumitra Thongprasert, et al.
Pageof 30

Showing results (281-290 of 292) with videos related to

Sort By:
Pageof 30
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 10, 2008
Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized, phase II studyLucio Crinò, Federico Cappuzzo, Petr Zatloukal, et al.
Journal of Medical Genetics|February 1, 1997
Pendred syndrome: evidence for genetic homogeneity and further refinement of linkageE Gausden, B Coyle, J A Armour, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 30, 2009
Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trialJean-Yves Douillard, Frances A Shepherd, Vera Hirsh, et al.
The Journal of Investigative Dermatology|December 18, 2009
Replication of LCE3C-LCE3B CNV as a risk factor for psoriasis and analysis of interaction with other genetic risk factorsUlrike Hüffmeier, Judith G M Bergboer, Tim Becker, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 10, 2019
Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trialW Shi, T Jiang, P Nuciforo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 9, 2017
Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trialW Shi, T Jiang, P Nuciforo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 28, 2018
Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trialW Shi, T Jiang, P Nuciforo, et al.
Teratogenesis, Carcinogenesis, and Mutagenesis|November 14, 2000
Molecular methods for the detection of mutationsC Monteiro, L A Marcelino, A R Conde, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 15, 2011
Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS)Masahiro Fukuoka, Yi-Long Wu, Sumitra Thongprasert, et al.
The New England Journal of Medicine|August 21, 2009
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinomaTony S Mok, Yi-Long Wu, Sumitra Thongprasert, et al.
Pageof 30